Investment Analysts’ Weekly Ratings Changes for Nabriva Therapeutics (NBRV)

Share on StockTwits

Nabriva Therapeutics (NASDAQ: NBRV) has recently received a number of price target changes and ratings updates:

  • 11/19/2019 – Nabriva Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 11/15/2019 – Nabriva Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
  • 11/14/2019 – Nabriva Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 11/13/2019 – Nabriva Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC.
  • 11/5/2019 – Nabriva Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/30/2019 – Nabriva Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/16/2019 – Nabriva Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/1/2019 – Nabriva Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

NASDAQ:NBRV traded down $0.03 during mid-day trading on Tuesday, reaching $1.81. The stock had a trading volume of 937,100 shares, compared to its average volume of 1,100,651. The firm has a 50 day moving average price of $1.92 and a two-hundred day moving average price of $2.18. The stock has a market capitalization of $1.39 billion, a P/E ratio of -1.11 and a beta of 2.42. Nabriva Therapeutics PLC – has a one year low of $1.12 and a one year high of $3.27. The company has a debt-to-equity ratio of 0.87, a quick ratio of 5.79 and a current ratio of 5.81.

Nabriva Therapeutics (NASDAQ:NBRV) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.04. The company had revenue of $6.92 million during the quarter, compared to the consensus estimate of $1.23 million. Nabriva Therapeutics had a negative return on equity of 171.36% and a negative net margin of 910.45%. Research analysts forecast that Nabriva Therapeutics PLC – will post -1.12 earnings per share for the current year.

In other news, CEO Theodore R. Schroeder bought 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was bought at an average price of $1.79 per share, for a total transaction of $89,500.00. Following the transaction, the chief executive officer now directly owns 5,786 shares of the company’s stock, valued at approximately $10,356.94. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders purchased 64,977 shares of company stock valued at $119,951 and sold 21,773 shares valued at $45,186. Insiders own 3.32% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Sterling Investment Advisors Ltd. lifted its position in Nabriva Therapeutics by 100.0% in the 3rd quarter. Sterling Investment Advisors Ltd. now owns 20,000 shares of the biotechnology company’s stock worth $40,000 after buying an additional 10,000 shares during the last quarter. Woodard & Co. Asset Management Group Inc. ADV bought a new stake in Nabriva Therapeutics in the 3rd quarter worth approximately $40,000. A.R.T. Advisors LLC bought a new stake in Nabriva Therapeutics in the second quarter valued at approximately $90,000. Parametric Portfolio Associates LLC lifted its position in Nabriva Therapeutics by 180.8% in the second quarter. Parametric Portfolio Associates LLC now owns 52,272 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 33,656 shares during the last quarter. Finally, Creative Planning bought a new stake in Nabriva Therapeutics in the third quarter valued at approximately $112,000. Institutional investors own 3.82% of the company’s stock.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Recommended Story: Support Level

Receive News & Ratings for Nabriva Therapeutics PLC - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics PLC - and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Great Panther Mining  Downgraded by Noble Financial to Hold
Great Panther Mining Downgraded by Noble Financial to Hold
Casella Waste Systems  Upgraded to Buy by Zacks Investment Research
Casella Waste Systems Upgraded to Buy by Zacks Investment Research
GENFIT S A/ADR  Upgraded to “Buy” by Zacks Investment Research
GENFIT S A/ADR Upgraded to “Buy” by Zacks Investment Research
SIG  Price Target Cut to GBX 122 by Analysts at Jefferies Financial Group
SIG Price Target Cut to GBX 122 by Analysts at Jefferies Financial Group
Xiaomi  Downgraded by Morgan Stanley to Underweight
Xiaomi Downgraded by Morgan Stanley to Underweight
Rio Tinto  Upgraded by Royal Bank of Canada to Sector Perform
Rio Tinto Upgraded by Royal Bank of Canada to Sector Perform


© 2006-2019 Ticker Report